Middle East Pouch Market

Chris co-founded Broughton in 2006, having worked previously within global blue-chip pharmaceutical companies and Contract Research Organisations within the medicinal product and medical device sectors.

· Over 25 years’ experience in Analytical and Regulatory Science focussing on inhaled and solid dose pharmaceuticals, medical devices, and nicotine products

· Extensive experience with global regulatory agencies, including US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA)

· Oversees the overall direction of the organisation, ensuring that Broughton’s mission is achieved

· Has a passion for developing Broughton’s services and team members to help accelerate life-enhancing products to market

Chris Allen is the Chief Executive Officer at Broughton. Since obtaining a Bachelor of Science degree in Chemistry and a subsequent Post Graduate Certificate in Analytical Science, he has gained over 25 years of analytical and regulatory experience working in global medical device and pharmaceutical companies and leading CROs. Chris started his career working on both Medical Devices and Pharmaceutical products within Smith+Nephew. Subsequently, Chris moved into inhaled medicines, supporting blue-chip pharmaceutical companies’ drug product registration programs within Melbourn Intertek.

Before co-founding Broughton, Chris moved into a leadership role with Sciantec (Cawood), successfully overseeing its entry into the Veterinary Medicines market, supporting global Marketing Authorizations and site inspections.

Chris co-founded Broughton Laboratories in 2006, with Paul Moran, overseeing its first and successful MHRA Good Manufacturing Practice (GMP) inspection within the first three months. With a focus on supporting Marketing Authorizations and Post Marketing activities within the pharmaceutical sector, Broughton played a pivotal role in obtaining the first UK Medicinal License for an electronic cigarette, a project that started in 2010.

Chris took this combined experience of Pharmaceuticals and Nicotine to expand Broughton’s services to support the development and registration of Reduced-Risk Tobacco Products, including Electronic Nicotine Delivery Systems (ENDS). Rapid growth within this area resulted in the expansion to a second site, and a multi-million-pound (GBP) investment into a custom-built facility, leading-edge analytical equipment, and expansion of the team and service offerings. Chris has overseen multiple product applications for Medicinal Marketing Authorization Applications (MAA), EU Tobacco Products Directive (TPD), US Premarket Tobacco Product

Application (PMTA) and other global markets. Chris has become well established as a recognized subject matter expert in the science and regulation of pharmaceuticals, medical devices and reduced risk nicotine products.

As Chief Executive Officer of Broughton, Chris’ passion lies in developing the Broughton Team and associated services to deliver life-enhancing products to market for their clients.

Fouad is a seasoned commercial expert in the NGP and FMCG industry, boasting over 25 years of experience in the MENA region. He currently serves as the Regional Director for the MEA region at DENSSI Nicotine Pouches.

Before joining DENSSI, Fouad led the RELX Tech business in Saudi Arabia and Kuwait during the challenging period of COVID-19. His extensive experience also includes a decade at Philip Morris International (PMI), where he held various commercial and strategic leadership roles.

Fouad's career began with notable positions at Mondelez and Nestlé Middle East, providing him with a strong foundation in the industry. He holds a Master’s degree in Corporate and Marketing Communication from IE University in Madrid.

Dr Hugo joined BAT in February 2022 and is a trained medical physician who holds an active annual practicing license from the Malaysia Medical Council. After practicing in both major public and private hospitals in Kuala Lumpur, he spent 14 years in medical affairs for multinational pharmaceutical organizations such as GlaxoSmithKline, Merck KGA, Novo Nordisk, Takeda. Hugo was formerly Medical and Regulatory Director for Novartis Oncology and AstraZeneca Hong Kong. He has worked with leading researchers in early and late phase clinical trials and partnered with biotech start-ups to bring innovative medicine from early development to commercialization. Hugo also completed an MBA from the Manchester Business School